The best indicator for Abbott Laboratories (ABT)
We backtested 20 indicators across daily, weekly and hourly charts on real Abbott Laboratories (ABT) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Stochastic
On the daily chart, this is the strongest risk-adjusted edge we found for Abbott Laboratories (ABT) over ~46.2 years — trailing buy-and-hold by 6.7% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Stochastic ✓ | Daily | 7.7% | 0.56 | -35.0% | 72.8% | 228 | -6.7% |
| 2 | WaveTrend (8/6/4) ✓ | Daily | 8.7% | 0.55 | -41.8% | 74.6% | 177 | -5.8% |
| 3 | SMA 50/200 Cross ✓ | Daily | 9.4% | 0.54 | -42.1% | 48.1% | 27 | -5.0% |
| 4 | EMA 20/50 Cross ✓ | Weekly | 9.3% | 0.54 | -38.2% | 45.0% | 20 | -5.0% |
| 5 | EMA 50/200 Cross ✓ | Daily | 8.5% | 0.5 | -39.2% | 40.7% | 27 | -5.9% |
| 6 | Holy Grail Confluence ✓ | Daily | 6.1% | 0.49 | -43.2% | 82.5% | 63 | -8.4% |
| 7 | RSI Trend (>50) ✓ | Weekly | 6.5% | 0.43 | -51.9% | 50.0% | 120 | -7.9% |
| 8 | Money Flow Index ✓ | Daily | 5.7% | 0.42 | -45.7% | 79.5% | 44 | -8.7% |
| 9 | Stochastic ✓ | Weekly | 4.8% | 0.42 | -34.7% | 73.2% | 41 | -9.6% |
| 10 | Williams %R ✓ | Daily | 5.5% | 0.4 | -42.1% | 71.3% | 303 | -9.0% |
| 11 | Donchian Breakout ✓ | Weekly | 5.5% | 0.4 | -57.6% | 50.0% | 40 | -8.9% |
| 12 | Bollinger Mean-Reversion ✓ | Daily | 4.5% | 0.39 | -42.8% | 71.3% | 171 | -10.0% |
| 13 | CCI ✓ | Daily | 5.2% | 0.39 | -39.2% | 73.8% | 221 | -9.3% |
| 14 | EMA 20/50 Cross ✓ | Daily | 5.6% | 0.38 | -40.8% | 43.0% | 100 | -8.8% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Abbott Laboratories (ABT), Stochastic on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.